Esegrow-D Tablets is primarily indicated in conditions like Hypocalcaemia of hypoparathyroidism, Hypoparathyroidism, Hypophosphataemia, Osteomalacia, Osteoporosis, Prevention of vitamin d deficiency, Renal osteodystrophy, Simple vitamin d deficiency, Vitamin D deficiency, Vitamin D deficiency rickets, and can also be given in adjunctive therapy as an alternative drug of choice in Malabsorption, Post gastrectomy vit B-12 deficiency, Renal diseases.
Esegrow-D Tablets is contraindicated in conditions like Hypercalcaemia.
The severe or irreversible adverse effects of Esegrow-D Tablets, which give rise to further complications include Cardiac arrhythmias, Cardiac arrhythmias, Paralytic ileus, Thirst, Dehydration, Polyuria, Nocturia, Abdominal paing Overt psychosis, Metastatic calcification, Hyperphosphatemia, Hypervitaminosis D.Esegrow-D Tablets produces potentially lifethreatening effects which include Cardiac arrhythmias, Renal failure, which are responsible for the discontinuation of Esegrow-D Tablets therapy. The symptomatic adverse reactions produced by Esegrow-D Tablets are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Headache, Nausea, vomiting, Anorexia, Apathy, Somnolence, Weakness.
Evaluate Vitamin D administration in fortified food, diet and drugs. It may be necessary to limit dietary Vitamin D during treatment. If products of Vitamin D contain tartrazine may cause allergic reaction (including bronchial asthma) in susceptible individuals, Specially patients with aspirin hypersensitivity. Take care to ensure correct dose infants,monitor plasma calcium concentration in patient receiving high dose and in renal impairment.